HC Wainwright Has Positive Outlook for SGMO Q3 Earnings

Sangamo Therapeutics, Inc. (NASDAQ:SGMO) – Equities researchers at HC Wainwright boosted their Q3 2025 EPS estimates for shares of Sangamo Therapeutics in a research note issued to investors on Wednesday, May 14th. HC Wainwright analyst P. Trucchio now forecasts that the biopharmaceutical company will post earnings of ($0.08) per share for the quarter, up from their prior forecast of ($0.11). HC Wainwright currently has a “Buy” rating and a $10.00 price target on the stock. The consensus estimate for Sangamo Therapeutics’ current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics’ FY2025 earnings at ($0.17) EPS, FY2026 earnings at ($0.17) EPS and FY2027 earnings at ($0.04) EPS.

A number of other research firms have also weighed in on SGMO. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $2.00 price objective on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Truist Financial dropped their price target on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Finally, Barclays cut their price target on Sangamo Therapeutics from $9.00 to $5.00 and set an “overweight” rating for the company in a research note on Wednesday, May 14th. Three research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $4.50.

Sangamo Therapeutics Stock Up 0.1%

NASDAQ SGMO opened at $0.50 on Monday. Sangamo Therapeutics has a 52 week low of $0.30 and a 52 week high of $3.18. The business has a 50 day moving average price of $0.71 and a 200-day moving average price of $1.30. The company has a market cap of $116.37 million, a price-to-earnings ratio of -0.67 and a beta of 1.46.

Sangamo Therapeutics (NASDAQ:SGMO) last released its quarterly earnings data on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.03). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $6.44 million for the quarter, compared to the consensus estimate of $7.90 million.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SGMO. Point72 Asset Management L.P. bought a new stake in shares of Sangamo Therapeutics during the 4th quarter valued at $2,316,000. Schonfeld Strategic Advisors LLC bought a new stake in Sangamo Therapeutics during the fourth quarter worth about $1,744,000. GSA Capital Partners LLP grew its holdings in Sangamo Therapeutics by 2,962.2% in the first quarter. GSA Capital Partners LLP now owns 966,202 shares of the biopharmaceutical company’s stock worth $634,000 after purchasing an additional 934,649 shares during the period. Acuta Capital Partners LLC bought a new position in shares of Sangamo Therapeutics during the fourth quarter valued at approximately $755,000. Finally, Two Sigma Advisers LP purchased a new position in shares of Sangamo Therapeutics during the fourth quarter valued at approximately $722,000. 56.93% of the stock is owned by hedge funds and other institutional investors.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.